ID   DMS 79
AC   CVCL_1178
SY   DMS-79; DMS79; Darmouth Medical School 79
DR   CLO; CLO_0002800
DR   CLO; CLO_0002802
DR   EFO; EFO_0002166
DR   CLDB; cl1082
DR   CLDB; cl4907
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-2049
DR   BioSample; SAMN03473247
DR   BioSample; SAMN10988337
DR   cancercelllines; CVCL_1178
DR   Cell_Model_Passport; SIDM00524
DR   ChEMBL-Cells; CHEMBL3307581
DR   ChEMBL-Targets; CHEMBL614286
DR   CLS; 300164
DR   Cosmic; 753551
DR   Cosmic; 1609526
DR   Cosmic; 2648007
DR   Cosmic-CLP; 753551
DR   DepMap; ACH-000703
DR   ECACC; 95062824
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   GDSC; 753551
DR   GEO; GSM17308
DR   GEO; GSM169445
DR   GEO; GSM886985
DR   GEO; GSM888054
DR   GEO; GSM1669738
DR   IARC_TP53; 21309
DR   ICLC; HTL98009
DR   IGRhCellID; DMS79
DR   LiGeA; CCLE_666
DR   LINCS_LDP; LCL-1832
DR   PharmacoDB; DMS79_301_2019
DR   PRIDE; PXD011896
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1178
DR   PubChem_Cell_line; CVCL_1178
DR   Wikidata; Q54831312
RX   PubMed=2986244;
RX   PubMed=6266631;
RX   PubMed=8383976;
RX   PubMed=9744504;
RX   PubMed=12712436;
RX   PubMed=15016488;
RX   PubMed=17426248;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=22460905;
RX   PubMed=22961666;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=25960936;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=35839778;
WW   http://www.cells-talk.com/index.php/page/copelibrary?key=DMS%2079
WW   https://tcpaportal.org/mclp/
WW   https://www.atcc.org/en/support/technical-support/faqs/normal-growth-of-item-crl-2049
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: MD Anderson Cell Lines Project.
CC   Population: Caucasian.
CC   Doubling time: 3.9 days (PubMed=6266631); 5.8 days (PubMed=2986244); ~4 days (CLS=300164).
CC   HLA typing: A*01:01,02:01; B*08:01,35:01; C*04:01,07:01; DQB1*03:09,05:03; DRB1*11:30,11:30 (PubMed=25960936).
CC   HLA typing: A*01:01,02:01; B*08:01,35:01; C*04:01,07:01; DQB1*03:09,05:03; DRB1*11:30,11:30 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 9683; PTPRU; Simple; p.Glu442Ter (c.1324G>T); Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Gly801Ter (c.2401G>T); Zygosity=Homozygous (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Glufs*65 (c.837delG) (p.G279fs); Zygosity=Unspecified (DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: Deep proteome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0.52%; Native American=0%; East Asian, North=0.95%; East Asian, South=0%; South Asian=1.45%; European, North=66.84%; European, South=30.24% (PubMed=30894373).
CC   Misspelling: DMS76; Note=In text of PubMed 20439192.
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): ATCC; CLS; Cosmic-CLP; DSMZ; ECACC; PubMed=25877200
ST   Amelogenin: X,Y
ST   CSF1PO: 10
ST   D13S317: 11
ST   D16S539: 12
ST   D18S51: 14,17
ST   D21S11: 30
ST   D3S1358: 18
ST   D5S818: 10
ST   D7S820: 9,11
ST   D8S1179: 12,14
ST   FGA: 21
ST   Penta D: 11,13
ST   Penta E: 7
ST   TH01: 8
ST   TPOX: 8
ST   vWA: 18
DI   NCIt; C4917; Lung small cell carcinoma
DI   ORDO; Orphanet_70573; Small cell lung cancer
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   65Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 40
//
RX   PubMed=2986244; DOI=10.1007/978-3-642-82372-5_5;
RA   Vindelov L.L., Hansen H.H., Spang-Thomsen M.;
RT   "Growth characteristics and heterogeneity of small cell carcinoma of
RT   the lung.";
RL   Recent Results Cancer Res. 97:47-54(1985).
//
RX   PubMed=6266631; DOI=10.1002/1097-0142(19800301)45:5<906::AID-CNCR2820450513>3.0.CO;2-H;
RA   Pettengill O.S., Sorenson G.D., Wurster-Hill D.H., Curphey T.J.,
RA   Noll W.W., Cate C.C., Maurer L.H.;
RT   "Isolation and growth characteristics of continuous cell lines from
RT   small-cell carcinoma of the lung.";
RL   Cancer 45:906-918(1980).
//
RX   PubMed=8383976; DOI=10.1677/jme.0.0100025;
RA   Farrell W.E., Stewart M.F., Clark A.J.L., Crosby S.R., Davis J.R.E.,
RA   White A.;
RT   "Glucocorticoid inhibition of ACTH peptides: small cell lung cancer
RT   cell lines are more resistant than pituitary corticotroph adenoma
RT   cells.";
RL   J. Mol. Endocrinol. 10:25-32(1993).
//
RX   PubMed=9744504; DOI=10.1038/bjc.1998.553;
RA   Damstrup L., Voldborg B.G.R., Spang-Thomsen M., Brunner N.,
RA   Poulsen H.S.;
RT   "In vitro invasion of small-cell lung cancer cell lines correlates
RT   with expression of epidermal growth factor receptor.";
RL   Br. J. Cancer 78:631-640(1998).
//
RX   PubMed=12712436; DOI=10.1002/ijc.11106;
RA   Hansen L.T., Lundin C., Spang-Thomsen M., Petersen L.N., Helleday T.;
RT   "The role of RAD51 in etoposide (VP16) resistance in small cell lung
RT   cancer.";
RL   Int. J. Cancer 105:472-479(2003).
//
RX   PubMed=15016488; DOI=10.1016/S0140-6736(04)15693-6;
RA   Jones M.H., Virtanen C., Honjoh D., Miyoshi T., Satoh Y., Okumura S.,
RA   Nakagawa K., Nomura H., Ishikawa Y.;
RT   "Two prognostically significant subtypes of high-grade lung
RT   neuroendocrine tumours independent of small-cell and large-cell
RT   neuroendocrine carcinomas identified by gene expression profiles.";
RL   Lancet 363:775-781(2004).
//
RX   PubMed=17426248; DOI=10.1158/1541-7786.MCR-06-0367;
RA   Olejniczak E.T., Van Sant C., Anderson M.G., Wang G., Tahir S.K.,
RA   Sauter G., Lesniewski R., Semizarov D.;
RT   "Integrative genomic analysis of small-cell lung carcinoma reveals
RT   correlates of sensitivity to bcl-2 antagonists and uncovers novel
RT   chromosomal gains.";
RL   Mol. Cancer Res. 5:331-339(2007).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=22961666; DOI=10.1158/2159-8290.CD-12-0112;
RA   Byers L.A., Wang J., Nilsson M.B., Fujimoto J., Saintigny P.,
RA   Yordy J., Giri U., Peyton M., Fan Y.-H., Diao L.-X., Masrorpour F.,
RA   Shen L., Liu W.-B., Duchemann B., Tumula P., Bhardwaj V., Welsh J.,
RA   Weber S., Glisson B.S., Kalhor N., Wistuba I.I., Girard L.,
RA   Lippman S.M., Mills G.B., Coombes K.R., Weinstein J.N., Minna J.D.,
RA   Heymach J.V.;
RT   "Proteomic profiling identifies dysregulated pathways in small cell
RT   lung cancer and novel therapeutic targets including PARP1.";
RL   Cancer Discov. 2:798-811(2012).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//